3-Dimethylamino-2-methylpyrazin | 56343-47-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-Dimethylamino-2-methylpyrazin
• 英文别名: N,N,3-Trimethylpyrazin-2-amine
• CAS: 56343-47-6
• 化学式: C₇H₁₁N₃
• 分子量: 137.184
• InChiKey: FVIOLJXJPWNFRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  29
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS<br/>[FR] CARBOXYLATES DE PIPÉRIDIN-1-YLE ET D'AZÉPIN-1-YLE À TITRE D'AGONISTES DU RÉCEPTEUR MUSCARINIQUE M4
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2014122474A1

  公开（公告）日：2014-08-14

  The present invention provides muscarinic M4 receptor agonists of formula (I) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, R, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases such as schizophrenia, Alzheimer's disease and various cognitive disorders as well as in the treatment or alleviation of pain.

  本发明提供了式（I）的肌氨酸M4受体激动剂及其药用盐，其中m、n、p、q、R、R2和R3如规范中所定义，其制备方法，含有它们的药物组合物以及它们在治疗精神分裂症、阿尔茨海默病和各种认知障碍以及治疗或缓解疼痛中的用途。
• PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS
  申请人：Wang Tao

  公开号：US20120095017A1

  公开（公告）日：2012-04-19

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

  本发明提供了具有药物和生物影响特性的化合物，它们的制药组合物和使用方法。特别地，本发明涉及氮杂吲哚酮乙酰基哌嗪衍生物。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染药物、免疫调节剂或HIV进入抑制剂联合使用。更具体地，本发明涉及治疗HIV和艾滋病。
• BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS
  申请人：Conn P. Jeffrey

  公开号：US20120225844A1

  公开（公告）日：2012-09-06

  In one aspect, the invention relates to bicyclic triazole and pyrazole lactams, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明涉及双环三唑和吡唑内酰胺、其衍生物和相关化合物，可作为代谢型谷氨酸受体亚型5（mGluR5）的正向变构调节剂；制备这些化合物的合成方法；包含这些化合物的制药组合物；以及使用这些化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神障碍的方法。本摘要旨在作为特定领域搜索的扫描工具，不限制本发明。
• PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES
  申请人：Bristol-Myers Squibb Company

  公开号：US20150329543A1

  公开（公告）日：2015-11-19

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

  本发明提供具有药物和生物影响特性的化合物，其制药组合物和使用方法。特别地，本发明涉及氮杂吲哚氧乙酰基哌嗪衍生物。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染剂、免疫调节剂或HIV进入抑制剂联合使用。更具体地，本发明涉及治疗HIV和艾滋病。
• SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES
  申请人：Bristol-Myers Squibb Company

  公开号：US20150259342A1

  公开（公告）日：2015-09-17

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives having the Formula I: wherein Q is These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

  本发明提供了具有药物和生物影响性质的化合物，它们的制药组合物和使用方法。特别地，本发明涉及具有式I的氮杂吲哌酮乙酰基哌嗪衍生物，其中Q为。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染药物、免疫调节剂或HIV进入抑制剂联合使用。更具体地，本发明涉及治疗HIV和艾滋病。